Quantcast

Industry news that matters to you.  Learn more

Archives for September 2010

Michael J. Fox Foundation Launches Parkinson’s Progression Markers Initiative (PPMI)

The Michael J. Fox Foundation has launched the Parkinson’s Progression Markers Initiative (PPMI) (www.michaeljfox.org/PPMI), the first-ever large-scale clinical study exclusively focused on identifying and validating Parkinson’s disease biomarkers.

Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement

Clinical Genomics Pty. Ltd. and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan’s proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer. Clinical Genomics intends to expand its colorectal biomarker research program to evaluate these promising biomarkers in view of formulating a diagnostic test utilizing those biomarkers demonstrating clinical benefit for the early detection of colorectal cancer.

Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology

Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, announced today that they have entered into a collaboration and licensce agreement to identify novel oncology targets for the development of new therapeutic agents directed at such targets and related biomarkers.

OncoMethylome Sciences Signs Agreement for the Potential Use of its Technology Platform in GlaxoSmithKline Biologicals Immunotherapy Development Program

OncoMethylome Sciences, a leading molecular diagnostics company, announced today that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.

Sophic Wins $750K in NCI Funding

Sophic Systems Alliance has reeled in a $750,000 grant from the National Cancer Institute to continue development of its Sophic Cancer Biomarker KnowledgeBase (Scan-Mark), which will be used in personalized cancer research.